PARP Inhibitors Consistently Improve PFS as First-Line Maintenance in Advanced Ovarian Cancer

Poly (ADP-ribose) polymerase (PARP) inhibitors as maintenance therapy are superior to other maintenance therapies on outcomes in advanced ovarian cancer, according to a systematic review of the literature.

In extracting data from 50 full-text journal articles covering 18 clinical trials, and examining efficacy outcomes, investigators led by Holly Guy, MSC, a health economist from FIECON, Ltd, St. Albans, UK, found improvements in progression-free survival (PFS) “across the board” with PARP inhibitor maintenance compared with other types of maintenance. In addition, “only PARP inhibitor-containing therapies reported significant overall survival [OS] hazard ratios [HRs] below 1 across all trial populations,” they wrote in their abstract presented during the European Society of Gynecological Oncology Virtual Congress 2020.

The 18 clinical trials assessed clinical outcomes with first-line maintenance therapies and maintenance therapies initiated alongside first-line chemotherapy followed by a maintenance phase for advanced ovarian cancer. Only 2 of the 18 did not report PFS as an efficacy end point.

Of those that assessed first-line maintenance with a PARP inhibitor with PFS reported, HRs were 0.766 for pazopanib versus placebo in the AGO-OVAR16 trial, 0.30 for olaparib versus placebo in SOLO-1, 1.114 for pazopanib versus placebo in an East Asian substudy of AGO-OVAR16, 0.98 for pazopanib versus placebo in NCT01227928, 0.59 for olaparib plus bevacizumab versus placebo plus bevacizumab in PAOLA-1, 0.62 for niraparib versus in PRIMA, and 0.68 for veliparib versus placebo in VELIA/GOG-3005.

“No pattern was identified in relation to PFS amongst patients who were treated with a maintenance therapy following first-line platinum-based chemotherapy versus those who received a maintenance drug concurrently with first-line platinum-based chemotherapy and then continued with the maintenance treatment,” the authors noted.

Of those that reported OS as a secondary end point, HRs for OS in the PARP inhibitor studies were 0.96 (AGO-OVAR16), 0.95 (SOLO-1), and 0.7 (PRIMA).

“Therapies that included PARP inhibitors reported better PFS HR than other ovarian cancer maintenance therapies,” the investigators concluded. “In study populations including both BRCA mutation-positive and wild type, clinical benefit is conferred by both olaparib plus bevacizumab and niraparib, as indicated by PFS.”

Related Articles

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: